Based on the analysis of Pharmagen's profitability, liquidity, and operating efficiency, Pharmagen is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Pharmagen's Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 9.8 M in 2024, whereas Total Assets are likely to drop slightly above 1.3 M in 2024. Key indicators impacting Pharmagen's financial strength include:
The essential information of the day-to-day investment outlook for Pharmagen includes many different criteria found on its balance sheet. An individual investor should monitor Pharmagen's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pharmagen.
Net Income
(5.13 Million)
Pharmagen
Select Account or Indicator
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Long Term Debt
Net Receivables
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Short Long Term Debt
Preferred Stock Total Equity
Total Current Assets
Intangible Assets
Common Stock
Property Plant Equipment
Selling General Administrative
Total Revenue
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Cost Of Revenue
Non Recurring
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Probability Of Bankruptcy
Understanding current and past Pharmagen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pharmagen's financial statements are interrelated, with each one affecting the others. For example, an increase in Pharmagen's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Pharmagen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pharmagen. Check Pharmagen's Beneish M Score to see the likelihood of Pharmagen's management manipulating its earnings.
Pharmagen Stock Summary
Pharmagen competes with Humana, Cigna Corp, Elevance Health, Centene Corp, and UnitedHealth Group. Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. PHARMAGEN INC operates under Medical Distribution classification in the United States and is traded on PNK Exchange. It employs 24 people.
Comparative valuation techniques use various fundamental indicators to help in determining Pharmagen's current stock value. Our valuation model uses many indicators to compare Pharmagen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmagen competition to find correlations between indicators driving Pharmagen's intrinsic value. More Info.
Pharmagen is rated below average in return on asset category among its peers. It also is rated below average in profit margin category among its peers . At this time, Pharmagen's Net Loss is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmagen's earnings, one of the primary drivers of an investment's value.
Pharmagen Systematic Risk
Pharmagen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharmagen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Pharmagen correlated with the market. If Beta is less than 0 Pharmagen generally moves in the opposite direction as compared to the market. If Pharmagen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharmagen is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharmagen is generally in the same direction as the market. If Beta > 1 Pharmagen moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Pharmagen is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Pharmagen has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Pharmagen's financials are consistent with your investment objective using the following steps:
Review Pharmagen's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Pharmagen's liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Pharmagen's financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Pharmagen's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.